Anti-Human Abeta Recombinant Antibody (Solanezumab) (CAT#: TAB-228)

Figure 1 shows the mean change over the course of 18 months of treatment with solanezumab or placebo for cognitive and functional outcomes.

For the ADAS-Cog14, as well as the ADAS-Cog11, significant differences between treatment groups were first observed at week 40 and were sustained through endpoint (week 80). For MMSE, the difference between treatment groups reached significance at endpoint. For the ADCS-iADL, significant differences between treatment groups were observed at week 64 and sustained through endpoint. No differences were evident between treatment groups for change from baseline on the ADCS-ADL, the ADCS-bADL subscale or the CDR-SB. The placebo versus active treatment group differences in the ADAS-Cog14 and ADCS-iADL increased over 18 months.

Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu-Seifert, H., ... & Demattos, R. (2016). Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimer's & Dementia, 12(2), 110-120.

Figure 1 Anti-Human Abeta Antibody in SDS-PAGE

SDS-PAGE analysis of TAB-228 in non-reduced (lane 1) and β-mercaptoethanol-reduced (lane 2) conditions.